Notice of Participation in the Luncheon Seminar at the 4th Annual Meeting of the Japanese Society for Antibody Research

Sartorius Stedim Japan K.K.

"Next-Generation CHO Cell Line Development Service Integrating AI and Process Intensification - Innovation of Sartorius CLD Workflow" In biopharmaceutical development, establishing high-quality cell lines in a short period has become increasingly important. Sartorius's Cell Line Development (CLD) service has supported the approval of 7 antibody products and over 80 clinical projects to date. Seminar Points: ■ The latest workflow that selects optimal clones by AI analysis of nano-well images and fluorescence data immediately after single-cell cloning with CellCelector ■ A series of CLD processes that continue from Clone Evaluation, quality analysis, scale-up, to technology transfer to CDMO ■ Process Intensification strategies based on High Inoculation Fed-Batch and Perfusion culture ■ Media optimization service that can be used independently (supporting non-GMP prototypes to GMP manufacturing scale) Date and Time: December 3 (Wednesday) 12:20–13:20 Venue: Omiya Sonic City, Exhibition Hall 2

Date and time Wednesday, Dec 03, 2025
12:20 PM ～ 01:20 PM
Capital Omiya Sonic City, 1-7-5 Sakuragi-cho, Omiya-ku, Saitama-shi, Saitama 330-8669, Sonic City Building
Entry fee Free Participation in the academic conference requires a fee, but there is no additional cost for attending the seminar.

Related product information

4Cell CHO Platform
Protein characterization analysis, cell banking, safety testing services

The foundation for the approval of new biopharmaceuticals is formed by a robust analytical data package that demonstrates the safety, purity, and efficacy of the product. Sartorius's analytical testing package combines physicochemical analysis methods with biological analysis methods, providing detailed characterization tailored to each customer. Our services enable rapid data-driven decision-making during drug development using platform methods, off-the-shelf assays, and custom-developed bioassays, available from preclinical to clinical stages and lot release.
Cell line development and upstream process services
Using Cellca cell line development, over 120 projects have been successfully completed.

【Main Elements】 ▪ Cell lines & tests ▪ 4Cell CHO medium system ▪ Expression vector ▪ Upstream process
4Cell Nutri-T Medium Serum-Free Medium
Excellent results and flexibility with xenofree serum-free medium for lymphocyte culture!

Benefits for Four Customers 〈Performance〉 ■ Excellent Fold Expansion ■ Superior survival rate and CD8+ expression rate ■ High transduction efficiency (%) for CAR-T applications 〈Flexibility〉 ■ Excellent results with healthy PBMCs, TILs, and CAR-T applications ■ Excellent results using cells derived from cancer patients ■ Outstanding results at low seeding concentrations 〈Safety〉 ■ Elimination of serum-related risks through serum-free conditions ■ Manufactured in compliance with ISO13408 guidelines ■ Robust shipping tests 〈Simplicity〉 ■ No need for serum raw materials, storage, or purchasing ■ Short lead times ensured by Nutri-T stock at our global facilities ■ Provision of our technical support and complementary products